Allakos Inc. (ALLK)
How ALLK actually reacts to news — the realized, point-in-time move the market made, measured across 264 labeled events over the last three years with zero look-ahead.
ALLK’s median reaction, across the day.
Email me when ALLK moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ALLK’s baseline. Nothing else.
Get “How ALLK reacts to news” as a PDF.
A free one-page summary: ALLK’s median reaction to news and the full breakdown by event type — the numbers on this page, in one page.
Recent ALLK events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Allakos Inc. | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT Allakos Inc. | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K Allakos Inc. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM Allakos Inc. | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS Allakos Inc. | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 10-Q Allakos Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -0.03% | |
| Form 10-K/A Allakos Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.93% | +1.22% | |
| Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share | Press release | GlobeNewswire | +1.73% | +2.98% | |
| ALLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Allakos Inc. Is Fair to Shareholders | Press release | Business Wire | +0.57% | +1.55% | |
| Form 8-K Allakos Inc. For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | +1.73% | +2.98% | |
| Form 8-K Allakos Inc. For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +0.04% | -3.14% | |
| Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results | Press release | GlobeNewswire | +4.74% | +2.04% | |
| Form 10-K Allakos Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +4.74% | +2.04% | |
| Form 8-K Allakos Inc. For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +4.74% | +2.04% | |
| Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring | Press release | GlobeNewswire | -3.30% | -21.23% | |
| Form 8-K Allakos Inc. For: Jan 27 | SEC filing · Form 8-K | SEC EDGAR | -3.30% | -21.23% | |
| Form S-8 Allakos Inc. | SEC filing · Form S-8 | SEC EDGAR | +1.74% | -5.99% | |
| Form 8-K Allakos Inc. For: Nov 15 | SEC filing · Form 8-K | SEC EDGAR | -0.95% | -3.81% | |
| Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results | Press release | GlobeNewswire | +0.00% | -2.17% | |
| Form 10-Q Allakos Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -2.17% | |
| Form 8-K Allakos Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.17% | |
| Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers | Press release | GlobeNewswire | -3.31% | -5.28% | |
| Form 8-K Allakos Inc. For: Oct 10 | SEC filing · Form 8-K | SEC EDGAR | -3.31% | -5.28% | |
| Form 8-K Allakos Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +3.02% | +4.09% | |
| Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results | Press release | GlobeNewswire | +0.00% | -0.03% | |
| Form 10-Q Allakos Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -0.03% | |
| Form 8-K Allakos Inc. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.03% | |
| Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile | Press release | GlobeNewswire | +1.79% | -5.36% | |
| Form 8-K Allakos Inc. For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +1.79% | -5.36% | |
| Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria | Press release | GlobeNewswire | -1.40% | -2.80% | |
| Form 8-K Allakos Inc. For: May 24 | SEC filing · Form 8-K | SEC EDGAR | -1.40% | -2.80% | |
| Form 8-K Allakos Inc. For: May 28 | SEC filing · Form 8-K | SEC EDGAR | -1.40% | -2.80% | |
| Allakos Provides Business Update and Reports First Quarter 2024 Financial Results | Press release | GlobeNewswire | +0.00% | -0.83% | |
| Form 10-Q Allakos Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -0.83% | |
| Form 8-K Allakos Inc. For: May 09 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.83% | |
| Form 8-K Allakos Inc. For: Apr 19 | SEC filing · Form 8-K | SEC EDGAR | +0.95% | -2.86% | |
| Form ARS Allakos Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.95% | -2.86% | |
| Form DEF 14A Allakos Inc. For: May 24 | SEC filing · Form DEF | SEC EDGAR | +0.95% | -2.86% | |
| Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results | Press release | GlobeNewswire | -1.55% | +1.55% | |
| Form 10-K Allakos Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.55% | +1.55% | |
| Form 8-K Allakos Inc. For: Mar 14 | SEC filing · Form 8-K | SEC EDGAR | -1.55% | +1.55% | |
| Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024 | Press release | GlobeNewswire | -1.80% | +5.04% | |
| Form 8-K Allakos Inc. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -1.80% | +5.04% | |
| Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition | Press release | GlobeNewswire | +5.15% | +2.21% | |
| Form 8-K Allakos Inc. For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | +5.15% | +2.21% | |
| Form 8-K Allakos Inc. For: Jan 31 | SEC filing · Form 8-K | SEC EDGAR | -0.79% | +0.79% | |
| Form 8-K Allakos Inc. For: Jan 16 | SEC filing · Form 8-K | SEC EDGAR | -0.46% | -5.99% | |
| Allakos Announces a Restructuring to Focus on Development of AK006 | Press release | GlobeNewswire | -1.73% | -2.46% | |
| Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints | Press release | GlobeNewswire | -1.73% | -2.46% | |
| Form 8-K Allakos Inc. For: Jan 16 | SEC filing · Form 8-K | SEC EDGAR | -0.46% | -5.99% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ALLK section they belong to.
More of the dataset.
ALLK earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.